StageSeries B | Alive
Last Raised$15M | 11 days ago
Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+160 points in the past 30 days
About Evergreen Theragnostics
Evergreen Theragnostics is a radiopharmaceutical contract development and manufacturing organization that provides theragnostic services. It offers services for therapeutic and centrally distributed diagnostic radiopharmaceuticals, from early development through commercialization. The company was founded in 2019 and is based in Springfield, New Jersey.
Missing: Evergreen Theragnostics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Evergreen Theragnostics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Evergreen Theragnostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Evergreen Theragnostics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest Evergreen Theragnostics News
Mar 15, 2023
Evergreen Theragnostics , a Springfield, NJ-based clinical stage contract development and manufacturing organization (CDMO), raised $15M in Series B funding. The backers were nor disclosed. The company intends to use the funds to prepare for the launch of Ga-68 DOTATOC, if approved. Activities will include building commercial capabilities and staffing, as well as inventory build. The product is planned to be available through Evergreen’s radiopharmacy partners around the country. Founded in 2019 and led by James Cook, President and CEO, Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals, being engaged in three core areas: CDMO, Products, and Drug Discovery. Leveraging the capital raise, the company is launching a new business unit, Evergreen Discovery, which is focused on developing novel radiopharmaceuticals for cancer therapy. To support its new business unit, Evergreen has recruited Dr. Thomas Reiner as their Chief Scientific Officer. Prior to this, Dr. Reiner served as Head of Radioligand Therapy Drug Discovery on the Executive Leadership Team of AAA (Advanced Accelerator Applications, a Novartis Company). He is a former Laboratory Head, Associate Professor and Member of the Chemical Biology Program at Memorial Sloan Kettering Cancer Center. Evergreen Discovery will be based in a new research facility near Princeton, NJ, opening in Q3’2023. FinSMEs
Evergreen Theragnostics Frequently Asked Questions (FAQ)
When was Evergreen Theragnostics founded?
Evergreen Theragnostics was founded in 2019.
Where is Evergreen Theragnostics's headquarters?
Evergreen Theragnostics's headquarters is located at 27 Commerce Street, Springfield.
What is Evergreen Theragnostics's latest funding round?
Evergreen Theragnostics's latest funding round is Series B.
How much did Evergreen Theragnostics raise?
Evergreen Theragnostics raised a total of $34.05M.
Who are the investors of Evergreen Theragnostics?
Investors of Evergreen Theragnostics include Club degli Investitori and Bank of America.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.